Toward Comprehensive Immunization: The Role of Combined COVID-19 and Influenza Vaccines in Public Health

Year : 2025 | Volume : 02 | Issue : 01 | Page : 9 17
    By

    Satish Kumar Sarankar,

  1. Professor & Principal, Faculty of Pharmacy, Mansarovar Global University, Sehore, MP, India

Abstract

The emergence of multi-pathogen vaccines, particularly those combining protection against COVID- 19 and influenza, marks a significant advancement in immunization efforts. These combination vaccines have the potential to streamline vaccination processes, improve vaccine uptake, and reduce the burden on healthcare systems by offering a single dose that targets both viruses. COVID-19 and seasonal influenza are major public health concerns, with overlapping symptoms and seasonal patterns that justify the rationale for a combined vaccine approach. Recent technological advancements, especially mRNA and viral vector platforms, have paved the way for the rapid development of these combination vaccines.This review explores the current progress in developing COVID-19 and flu combo vaccines, highlighting key players, clinical trials, and the potential public health benefits. It also addresses the challenges, such as immune interference, manufacturing complexities, and regulatory hurdles that must be overcome for successful implementation. Furthermore, the implications for public health, including increased vaccination rates, cost- effectiveness, and reduced strain on healthcare systems, are discussed.Ensuring equitable global access and distribution of these vaccines is crucial to their impact, especially in resource-limited settings. Looking forward, the review touches on future innovations, including the development of vaccines targeting other respiratory pathogens and the potential for universal vaccines. The combined COVID-19 and flu vaccine represents a promising step toward more comprehensive and efficient vaccination strategies, contributing to improved global health outcomes.

Keywords: COVID-19, Influenza, Multi-Pathogen Vaccines, mRNA Vaccine Technology, Public Health Immunization.

[This article belongs to International Journal of Vaccines ]

How to cite this article:
Satish Kumar Sarankar. Toward Comprehensive Immunization: The Role of Combined COVID-19 and Influenza Vaccines in Public Health. International Journal of Vaccines. 2024; 02(01):9-17.
How to cite this URL:
Satish Kumar Sarankar. Toward Comprehensive Immunization: The Role of Combined COVID-19 and Influenza Vaccines in Public Health. International Journal of Vaccines. 2024; 02(01):9-17. Available from: https://journals.stmjournals.com/ijv/article=2024/view=183670


References

  1. Nowak MD, Sordillo EM, Gitman MR, Mondolfi AE. Coinfection in SARS‐CoV‐2 infected patients: where are influenza virus and rhinovirus/enterovirus?. Journal of medical virology. 2020 Oct;92(10):1699.
  2. Yue H, Zhang M, Xing L, Wang K, Rao X, Liu H, Tian J, Zhou P, Deng Y, Shang J. The epidemiology and clinical characteristics of co‐infection of SARS‐CoV‐2 and influenza viruses in patients during COVID‐19 outbreak. Journal of medical virology. 2020 Nov;92(11):2870-3.
  3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. jama. 2020 Mar 17;323(11):1061-9.
  4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
  5. Cox R. Correlates of protection to influenza virus, where do we go from here?. Human vaccines & immunotherapeutics. 2013 Feb 1;9(2):405-8.
  6. Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert review of vaccines. 2016 Aug 2;15(8):967-76.
  7. Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, Soriano A, Piñeiro GJ. SARS-CoV-2 and influenza virus co-infection. Lancet (London, England). 2020 May 16;395(10236):e84.
  8. Zheng X, Wang H, Su Z, Li W, Yang D, Deng F, Chen J. Co-infection of SARS-CoV-2 and Influenza virus in Early Stage of the COVID-19 Epidemic in Wuhan, China. The Journal of Infection. 2020 Aug;81(2):e128.
  9. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, Li Q, Gu S, Xu T, Li Y, Lu B. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerging infectious diseases. 2020 Jun;26(6):1324.
  10. Ma L, Yang J, Zhang T, Han X, Huang Q, Yang Y, Feng L, Yang W, Wang C. Willingness toward COVID-19 vaccination, coadministration with other vaccines and receive a COVID-19 vaccine booster: A cross-sectional study on the guardians of children in China. Human vaccines & immunotherapeutics. 2022 Nov 30;18(5):2049169.
  11. Arevalo CP, Bolton MJ, Le Sage V, Ye N, Furey C, Muramatsu H, Alameh MG, Pardi N, Drapeau EM, Parkhouse K, Garretson T. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022 Nov 25;378(6622):899-904.
  12. Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoewojo S, Sofiatin Y, Khrisna CV, Sari RM, Setyaningsih L, Surachman F, Bachtiar NS. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: an interim analysis in Indonesia. Vaccine. 2021 Oct 22;39(44):6520-8.
  13. Lauring AS, Jones JO, Andino R. Rationalizing the development of live attenuated virus vaccines. Nature biotechnology. 2010 Jun;28(6):573-9.
  14. Wang Y, Yang C, Song Y, Coleman JR, Stawowczyk M, Tafrova J, Tasker S, Boltz D, Baker R, Garcia L, Seale O. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proceedings of the National Academy of Sciences. 2021 Jul 20;118(29):e2102775118.
  15. Wallis J, Shenton DP, Carlisle RC. Novel approaches for the design, delivery and administration of vaccine technologies. Clinical & Experimental Immunology. 2019 May;196(2):189-204.
  16. Nascimento IP, Leite L. Recombinant vaccines and the development of new vaccine strategies. Brazilian journal of medical and biological research. 2012;45:1102-11.
  17. Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Therapeutic delivery. 2016 May 1;7(5):319-34.
  18. Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJ. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. International journal of pharmaceutics. 2021 May 15;601:120586.
  19. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014 Jul 29;2(3):624-41.
  20. Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B, Audonnet JC. Development and registration of recombinant veterinary vaccines: the example of the canarypox vector platform. Vaccine. 2007 Jul 26;25(30):5606-12.
  21. Tan M, Jiang X. Recent advancements in combination subunit vaccine development. Human vaccines & immunotherapeutics. 2017 Jan 2;13(1):180-5.
  22. Gary EN, Weiner DB. DNA vaccines: prime time is now. Current Opinion in Immunology. 2020 Aug 1;65:21-7.
  23. Suschak JJ, Williams JA, Schmaljohn CS. Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Human vaccines & immunotherapeutics. 2017 Dec 2;13(12):2837-48.
  24. Zhang NN, Li XF, Deng YQ, Zhao H, Huang YJ, Yang G, Huang WJ, Gao P, Zhou C, Zhang RR, Guo Y. A thermostable mRNA vaccine against COVID-19. Cell. 2020 Sep 3;182(5):1271-83.
  25. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, Loschko J. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 Apr 8;592(7853):283-9.
  26. Morens DM, Taubenberger JK, Fauci AS. Universal coronavirus vaccines—an urgent need. New England Journal of Medicine. 2022 Jan 27;386(4):297-9.
  27. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. Jama. 2021 Apr 6;325(13):1318-20.
  28. Kinoshita T, Watanabe K, Sakurai Y, Nishi K, Yoshikawa R, Yasuda J. Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters. Scientific reports. 2021 Oct 28;11(1):21259.
  29. Achdout H, Vitner EB, Politi B, Melamed S, Yahalom-Ronen Y, Tamir H, Erez N, Avraham R, Weiss S, Cherry L, Bar-Haim E. Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. Nature Communications. 2021 Oct 5;12(1):5819.
  30. Ura T, Yamashita A, Mizuki N, Okuda K, Shimada M. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021 Jan 8;39(2):197-201.
  31. Gao T, Ren Y, Li S, Lu X, Lei H. Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Microbial Cell Factories. 2021 May 5;20(1):95.
  32. Rosales-Mendoza S, Solís-Andrade KI, Márquez-Escobar VA, González-Ortega O, Bañuelos-Hernandez B. Current advances in the algae-made biopharmaceuticals field. Expert Opinion on Biological Therapy. 2020 Jul 2;20(7):751-66.
  33. Ward BJ, Makarkov A, Séguin A, Pillet S, Trépanier S, Dhaliwall J, Libman MD, Vesikari T, Landry N. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥ 65 years): two multicentre, randomised phase 3 trials. The Lancet. 2020 Nov 7;396(10261):1491-503.
  34. Dadashi M, Khaleghnejad S, Abedi Elkhichi P, Goudarzi M, Goudarzi H, Taghavi A, Vaezjalali M, Hajikhani B. COVID-19 and influenza co-infection: a systematic review and meta-analysis. Frontiers in medicine. 2021 Jun 25;8:681469.
  35. Focosi D, Maggi F, Casadevall A. Mucosal vaccines, sterilizing immunity, and the future of SARS-CoV-2 virulence. Viruses. 2022 Jan 19;14(2):187.
Regular Issue Subscription Review Article
Volume 02
Issue 01
Received 23/09/2024
Accepted 09/10/2024
Published 16/11/2024
Publication Time 54 Days
375

Login


My IP

PlumX Metrics